Ensysce Biosciences (ENSC) vs CytoMed Therapeutics (GDTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CytoMed Therapeutics is the larger company by market cap ($10.6 million vs $10.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENSC | GDTC |
|---|---|---|
| Share price | $0.527 | $0.89 |
| Market cap | $10.25M | $10.62M |
| 1-day change | +15.07% | -5.81% |
| YTD return | — | -29.22% |
| 1-year return | — | -56.46% |
| EPS (TTM) | $-2.47 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.75 | $3.68 |
| 52-week low | $0.23 | $0.68 |
| Distance from 52-week high | -80.84% | -75.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +1465.46% | +367.42% |
| Average volume | 14.21M | 78.66K |
| Shares outstanding | 19.46M | 11.93M |
| Employees | 8 | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
ENSC vs GDTC FAQ
Which is bigger, Ensysce Biosciences or CytoMed Therapeutics?
CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $10.62M compared with $10.25M for Ensysce Biosciences (ENSC).
Are Ensysce Biosciences and CytoMed Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.